No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
FDA Accepts Amneal/mAbxience’s Denosumab BLA for Review
On 3 March 2025, Amneal Pharmaceuticals and mAbxience announced that the FDA has accepted for review their aBLA for two new denosumab biosimilars referencing Amgen’s Prolia® and Xgeva®…